NCT04452292: Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma

NCT04452292
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine Tumor (NET)
Recruitment Status: Recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received up to two cycles of chemotherapy prior to enrollment
Exclusions: 
https://ClinicalTrials.gov/show/NCT04452292

Comments are closed.

Up ↑